ArticleJournal of autoimmunity2018
TRIF deficiency protects non-obese diabetic mice from type 1 diabetes by modulating the gut microbiota and dendritic cells.
Article in Journal of autoimmunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- The Specific Alteration of Gut Microbiota in Diabetic Kidney Diseases-A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Pooled it
- Diacerein Protects Against Obesity-Related Cardiovascular Injury: Evidence from In Silico and In Vivo Studies.Applied biochemistry and biotechnology · 2026Article
- Gut Microbiota and Autoimmune Diseases: The Therapeutic Potential of Probiotics.Current microbiology · 2026Review
- Advances in the study of the interaction between schistosome infections and the host's intestinal microorganisms.Parasites & vectors · 2024Review
- Urinary microbiome profiling as a non-invasive tool for identifying biomarkers in systemic lupus erythematosus and lupus nephritis.Frontiers in cellular and infection microbiology · 2024Article
- TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model.Frontiers in immunology · 2024Article
- Mutual modulation of gut microbiota and the immune system in type 1 diabetes models.Nature communications · 2023Article
- Mechanistic insights into the role of probiotics in modulating immune cells in ulcerative colitis.Immunity, inflammation and disease · 2023Review
- The Gut Microbiota of Pregnant Rats Alleviates Fetal Growth Restriction by Inhibiting the TLR9/MyD88 Pathway.Journal of microbiology and biotechnology · 2023Article
- Hypoglycemic mechanisms ofHeliyon · 2023Article
- Host gene effects on gut microbiota in type 1 diabetes.Biochemical Society transactions · 2022Review
- Effect of Lactobacillus dominance modified by Korean Red Ginseng on the improvement of Alzheimer's disease in mice.Journal of ginseng research · 2022Article
- New Insights into Stroke Prevention and Treatment: Gut Microbiome.Cellular and molecular neurobiology · 2022Review
- Host-microbiota interactions shaping T-cell response and tolerance in type 1 diabetes.Frontiers in immunology · 2022Review
- Gut Microbiota-Modulated Metabolomic Profiling Shapes the Etiology and Pathogenesis of Autoimmune Diseases.Microorganisms · 2021Review
- Review
- The crucial role of early-life gut microbiota in the development of type 1 diabetes.Acta diabetologica · 2021Review
- Inflammasomes and Type 1 Diabetes.Frontiers in immunology · 2021Review
- Alteration of the fecal microbiota in Chinese patients with Schistosoma japonicum infection.Parasite (Paris, France) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
Abstract
The incidence of type 1 diabetes (T1D) is determined by both genetic and environmental factors. In recent years, the gut microbiota have been identified to be an important environmental factor that could modify diabetes susceptibility. We have previously shown that Myeloid differentiation primary response gene 88 (MyD88), a major adaptor protein downstream of most innate immune Toll-like receptor (TLR) signaling, is important for mediating diabetes susceptibility in the non-obese diabetic (NOD) mouse model of human T1D. Here we report the role of TIR-domain-containing adapter-inducing interferon-β (TRIF) in T1D development, as TRIF is an important adaptor protein downstream of TLR3 and TLR4 signaling. We found that TRIF-deficient (TRIF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.